SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 11, 2017, Pages 841-843

  Petrie, John R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; SOTAGLIFLOZIN; ANTIDIABETIC AGENT;

DRUG APPROVAL; DRUG EFFICACY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT WITHDRAWAL; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85029451465     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30315-7     Document Type: Note

References (13)

1. George, P, McCrimmon, RJ, Potential role of non-insulin adjunct therapy in type 1 diabetes. Diabet Med 30 (2013), 179–188.
2. Wilding, JP, Rajeev, SP, DeFronzo, RA, Positioning SGLT2 inhibitors/incretin-based therapies in the treatment algorithm. Diabetes Care 39:suppl 2 (2016), S154–S164.
3. Zinman, B, Wanner, C, Lachin, JM, et al., for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
4. Neal, B, Perkovic, V, Mahaffey, KW, et al., for the CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
5. Peters, AL, Buschur, EO, Buse, JB, Cohan, P, Diner, JC, Hirsch, IB, Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 (2015), 1687–1693.
6. US Food and Drug Administration. Sodium-glucose cotransporter-2 (SGLT2) inhibitors. https://www.fda.gov/Drugs/DrugSafety/ucm446852.htm (accessed Aug 16, 2017).
7. Henry, RR, Thakkar, P, Tong, C, Polidori, D, Alba, M, Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 38 (2015), 2258–2265.
8. Ferrannini, E, Baldi, S, Frascerra, S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65 (2016), 1190–1195.
9. Bonner, C, Kerr-Conte, J, Gmyr, V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 21 (2015), 512–517.
10. Dandona, P, Mathieu, C, Phillip, M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol, 2017 published online Sept 14. http://dx.doi.org/10.1016/S2213-8587(17)30308-X.
11. Buse, JB, Garg, SK, Rosenstock, J, et al. Twenty four week efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem1). Diabetes, 66(suppl 1), 2017, A18 (69-OR).
12. Mathieu, C, Zinman, B, Hemmingsson, JU, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care 39 (2016), 1702–1710.
13. Petrie, JR, Chaturvedi, N, Ford, I, et al., for the REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5 (2017), 597–609.